TY  - BOOK
AU  - McCarron, Edward C
AU  - Swain, Sandra M
TI  - Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30
SN  - 0027-8874
PY  - 2018///
KW  - *Antineoplastic Combined Chemotherapy Protocols/ae [Adverse Effects]
KW  - *Antineoplastic Combined Chemotherapy Protocols/tu [Therapeutic Use]
KW  - *Breast Neoplasms/dt [Drug Therapy]
KW  - *Peripheral Nervous System Diseases/ci [Chemically Induced]
KW  - Chemotherapy, Adjuvant
KW  - Cyclophosphamide/ae [Adverse Effects]
KW  - Doxorubicin/ad [Administration & Dosage]
KW  - Doxorubicin/ae [Adverse Effects]
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Middle Aged
KW  - Quality of Life
KW  - Taxoids/ad [Administration & Dosage]
KW  - Taxoids/ae [Adverse Effects]
KW  - MedStar Franklin Square Medical Center
KW  - Washington Cancer Institute
KW  - Journal Article
N1  - Available online from MWHC library: 1996 - present (after 1 year), Available in print through MWHC library: 1999 - 2006
N2  - Background: The long-term effects of chemotherapy are sparsely reported. Peripheral neuropathy (PN) is one of the most frequent toxicities associated with taxane use for the treatment of early-stage breast cancer. We investigated the impact of the three different docetaxel-based regimens and patient characteristics on long-term, patient-reported outcomes of PN and the impact of PN on long-term quality of life (QOL); Conclusions: The administration of docetaxel is associated with long-term PN. The lower rate of long-term PN in AT and ACT patients might be an important consideration in supporting choosing these therapies for individuals with preexisting neuropathic symptoms or other risk factors for neuropathy; Methods: The National Surgical Adjuvant Breast and Bowel Project Protocol B-30 was a randomized trial comparing sequential doxorubicin (A) and cyclophosphamide (C) followed by docetaxel (T) (AC->T), concurrent ACT, or AT in women with node-positive, early-stage breast cancer. The AC->T group had a higher cumulative dose of T. PN was one of the symptoms assessed in a QOL substudy. Statistical methods included simple and mixed ordinal logistic regression and general linear models. All statistical tests were two-sided; Results: Of 1512 patients, 41.9% reported PN two years after treatment initiation. Treatment with AT and ACT was associated with less severe long-term PN compared with AC->T (odds ratio [OR] = 0.45, 95% confidence interval [CI] = 0.35 to 0.58; OR=0.59, 95% CI=0.46 to 0.75). Preexisting PN, older age, obesity, mastectomy, and greater number of positive nodes were also associated with higher risk of long-term PN. Patients who reported worse PN symptoms at 24months had statistically significantly worse QOL (Ptrend < .001)
UR  - https://dx.doi.org/10.1093/jnci/djx162
ER  -